ERBB2 and breast cancer: However, the combination of anthracyclines and trastuzumab regimen resulted in higher incidences of cardiac toxicity (2.9% vs 0.8% at 12 weeks), respectively.238 Trastuzumab combined with docetaxel and carboplatin achieved good pCR rate and tolerance for stage II and III HER2-positive breast cancer in trastuzumab-based neoadjuvant therapy, resulting from the GETN (A)-1 trial.239